Skip to main content
Download PDF

Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema

BMC Nephrology volume 23, Article number: 348 (2022) Cite this article

A Correction to this article was published on 28 November 2022

This article has been updated

Abstract

Background

Vascular endothelial growth factor inhibitors (VEGFIs) are used to treat malignant neoplasms and ocular diseases by inhibiting angiogenesis. Systemic use of VEGFIs has various side effects, including hypertension, proteinuria, and thrombotic microangiopathy, but adverse events due to intravitreal injection of VEGFIs have not been fully clarified. Although age-related macular degeneration was initially the most common target of intravitreal injection of VEGFIs, it has also been applied sporadically for diabetic macular edema in recent years. Proteinuria following intravitreal injection of VEGFIs would be reversible. In patients with diabetes mellitus (DM), however, it would be difficult to determine whether kidney damage arises from the clinical course of DM or from intravitreal injection of VEGFIs for diabetic macular edema.

Case presentation

A 55-year-old woman with a 20-year history of type 2 DM began intravitreal injection of VEGFI (aflibercept, 2 mg every 4 weeks) for treatment of diabetic macular edema 2 years previously. She presented with leg edema, hypertension, and nephrotic-range proteinuria 14 months after the first injection. Histological examination of renal biopsy specimens revealed diabetic nephropathy with renal thrombotic microangiopathy probably associated with intravitreal injection of VEGFI. The patient’s nephrotic syndrome completely improved at 6 months after simply discontinuing aflibercept.

Conclusions

This is a precious report of pathologically investigated renal thrombotic microangiopathy leading to nephrotic syndrome due to intravitreal injection of aflibercept for diabetic macular edema in a patient with type 2 DM. Renal function and proteinuria should be monitored in diabetic patients who receive intravitreal injection of a VEGFI. If kidney damage develops independent of the clinical course of DM during intravitreal injection of a VEGFI, renal biopsy should be performed and intravitreal VEGFI injection discontinued.

Peer Review reports

Background

Vascular endothelial growth factor inhibitors (VEGFIs) are used to treat malignant neoplasms and ocular diseases by inhibiting angiogenesis. Systemic use of VEGFIs is associated with various side effects, including hypertension, proteinuria, and thrombotic microangiopathy (TMA) [1,2,3]. In addition to promoting angiogenesis, vascular endothelial growth factor (VEGF) also maintains the morphology and function of vascular endothelial cells [1,2,3]. Therefore, blockade of VEGF signaling may also cause damage to glomerular vascular endothelial cells [1,2,3], leading to renal TMA.

VEGF levels are significantly increased in the eyeballs of patients with diabetic retinal angiopathy, which in turn promotes angiogenesis [4]. Therefore, intravitreal injection of VEGFIs is also used to inhibit VEGF signaling and prevent neoangiogenesis in those patients [4]. The intravitreal dose of VEGFI for the treatment of diabetic retinal vasculopathy is approximately 100- to 200-fold lower than the systemic dose used in the treatment of malignant neoplasms [1, 2].

Here, we report a case of nephrotic syndrome due to renal TMA that developed despite intravitreal injection of a VEGFI (aflibercept) in a female patient with diabetic macular edema (DME). Her nephrotic syndrome improved at 6 months after aflibercept discontinuation.

Case presentation

A 55-year-old woman with a 20-year history of type 2 diabetes mellitus (DM) was treated with basal-bolus insulin and oral hypoglycemic agents. She sometimes interrupted diabetic treatment, resulting in remaining high hemoglobin A1C (10%–14%) throughout her clinical course. She started intravitreal injection of aflibercept (2 mg every 4 weeks) for the treatment of DME 2 years previously. At initiation of aflibercept, her serum creatinine was 0.54 mg/dL and urinalysis showed no abnormalities. In 1- or 2-monthly monitoring of urinalysis, mild proteinuria (1 +) was found at 5 months after the first injection, but the injections were continued. Fourteen months after the first injection, she reported bilateral leg edema and hypertension (159/87 mm Hg) with a urine protein level of 4.9 g/gCr, urine red blood cells of 0–1/high-power field, and serum creatinine of 0.65 mg/dL; thus, amlodipine, telmisartan, and furosemide were added to the therapy. Nevertheless, urine protein continued to increase, to 10.0 g/gCr at 2 years after the first injection, and she was referred to our division for treatment of nephrotic-range proteinuria. A total dose of 44 mg of aflibercept was administered in 22 injections during the 2 years following the first injection, which halted the deterioration in eyesight. At the time of visiting our division, her other prescription medications included nifedipine, doxazosin mesylate, trichlormethiazide, spironolactone, rosuvastatin calcium, insulin glulisine, and insulin glargine. She had no family history of kidney disease or TMA.

The patient’s height was 155 cm, weight 64.3 kg, blood pressure 168/87 mm Hg, pulse 81/ min, O2 saturation 96% with room air, body temperature 37.4℃, and bilateral leg edema was noted. Computed tomography showed bilateral pleural and peritoneal effusions, but the kidneys were of normal size. Laboratory data revealed the following: white blood cell count, 4.59 × 103/μL; hemoglobin, 8.2 g/dL; platelet count, 21.3 × 104/μL; urine protein, 12.0 g/gCr; urine red blood cells, 10–19/high-power field; serum creatinine, 1.20 mg/dL; estimated glomerular filtration rate (using the 2021 CKD-EPI creatinine equation), 53.5 mL/min/1.73m2; serum albumin, 2.3 g/dL; hemoglobin A1C, 8.0%. No abnormalities were observed in IgG, IgA, IgM, C3, C4 levels, or autoantibodies. She had severe grade diabetic complication, such as proliferative diabetic retinopathy and diabetic neuropathy.

Two renal biopsy specimens were obtained for histological examination. There were 32 glomeruli in the light microscopic specimens, five of which were globally sclerotic. Glomeruli showed diffuse increase of mesangial matrix with nodular lesions (Fig. 1a). Mesangiolysis (Fig. 1b, arrow), duplication of the glomerular capillary wall (Fig. 1a, arrows), and expansion of the subendothelial spaces (Fig. 1a, arrowhead) were also present in the glomeruli. There were no definite thrombi in the glomeruli. Interstitial fibrosis, interstitial inflammation, and tubular atrophy were mild. Arterial sclerosis was mild, and arteriolar hyalinosis was moderate. No narrowing of the lumen or thrombosis were observed in the interstitial arterioles. Immunofluorescence studies showed linear IgG staining along the glomerular capillary walls (Fig. 1c; IgG 1 + , intensity) and negative staining for IgA, IgM, C3, and C1q. Electron microscopy revealed diffuse thickening of the glomerular basement membrane (GBM) and increased deposition of mesangial matrix in the glomeruli. Mesangiolysis, duplication of the GBM, and expansion of the subendothelial spaces were also seen (data not shown). Some expanded subendothelial spaces contained fibrin tactoids (Fig. 1d, arrowheads) and platelets (Fig. 1d, arrow). There were no electron-dense deposits in the glomeruli and some endothelial swellings were observed in the interstitial arterioles. Collectively, these findings suggested a final diagnosis of diabetic nephropathy with renal TMA probably associated with VEGFI (aflibercept).

Fig. 1
figure 1

Renal biopsy findings. a A light microscopy showing a glomerulus with nodular lesions, duplication of the glomerular capillary wall (arrows) and expansion of the subendothelial space (arrowhead) (periodic acid-Schiff stain, original magnification × 500). b Mesangiolysis (arrow) in the glomerulus (periodic acid-Schiff stain, original magnification × 800). c Immunofluorescence staining for IgG showing linear pattern along the glomerular capillary walls (original magnification × 400). d Electron microscopy showing expansion of the subendothelial space with fibrin tactoids (arrowheads) and platelet (arrow) (original magnification × 4000)

Full size image

Intravitreal aflibercept injection was discontinued after the renal biopsy, then both urinary protein and serum albumin gradually improved. Six months after withdrawal of aflibercept, the patient no longer had nephrotic syndrome as indicated by improvement of leg edema and disappearance both of the bilateral pleural effusion and ascites. Ten months after ceasing aflibercept, her laboratory parameters (serum creatinine, 1.49 mg/dL; serum albumin, 4.0 g/dL; urine protein, 0.6 g/gCr) and blood pressure (123/54 mm Hg) had improved. Her eyesight maintained stable even after aflibercept discontinuation.

Discussion and conclusions

In animal studies, VEGFI binding was detected in the glomeruli of monkeys after intravitreal injection of VEGFI [5]. Although experimental studies did not demonstrate a significant association between intravitreal injection of VEGFIs and renal dysfunction or proteinuria [6,7,8,9], some clinical studies suggesting an association between VEGFIs and renal dysfunction or proteinuria are beginning to appear [10, 11]. Hypertension has not been clearly demonstrated as a side effect of intravitreal injection of VEGFIs; however, there has been a recent increase in positive clinical studies reporting a relationship between them [6, 7, 12,13,14,15]. The associations of intravitreal injection of VEGFIs with increased risk of cerebrovascular events and mortality have also been controversial [16,17,18,19,20]. Therefore, adverse events due to intravitreal injection of VEGFIs have yet to be fully clarified.

In 2011, Pellé et al. first reported the pathology of renal biopsy (renal TMA) after intravitreal injection of VEGFI [21]. To date, 18 renal biopsies have been reported following intravitreal injection of VEGFIs (Table 1) [21,22,23,24,25,26,27,28,29,30,31,32,33,34]. In Japan, ranibizumab and aflibercept are used as intravitreal VEGFIs for age-related macular degeneration (AMD) and DME. Intravitreal injection of bevacizumab is also performed as an off-label use. AMD was initially the most common disease targeted by intravitreal injection of VEGFI, and its additional application for DME has been sporadic in recent years. We found more reports of renal biopsy after the use of intravitreal bevacizumab than those of ranibizumab and aflibercept, which may suggest that intravitreal bevacizumab has higher potency, longer half-time, and stronger systemic absorption [35, 36]. The treatment burden of patients with DME has been heavy with increasing number of diabetic patients [37], and the use of VEGFI for DME is also possibly increasing. Renal TMA was the most common renal pathology among the 18 renal biopsies, being reported in 9/18 patients (Nos. 1, 4, 9, 10, and 14–18 in Table 1) [21, 23, 28, 29, 32,33,34]. Of these, only three patients showed improvement after discontinuation of intravitreal injection of VEGFI for AMD or glaucoma (Nos. 1, 9 and 18 in Table 1) [21, 28, 34]. In our case, renal TMA developed due to intravitreal aflibercept injection for DME—not for AMD or glaucoma—and the condition improved after simply discontinuing intravitreal injection of aflibercept, without the use of corticosteroids or other drugs.

The glomerular changes in the present case are consistent pathologically with diabetic nephropathy (class III); however, considering the doubling of the glomerular capillary wall (basement membrane) and expansion of the subendothelial space, the morphological findings are also compatible with renal TMA [38]. In fact, the improvement of proteinuria after discontinuing intravitreal aflibercept suggests that the primary cause of proteinuria was renal TMA due to intravitreal aflibercept rather than coexisted diabetic nephropathy.

There have been reports of TMA improvement after discontinuing of intravitreal injection of VFGFI for AMD and glaucoma [21, 28, 34]. To the best of our knowledge, this is a precious report of renal TMA that developed due to intravitreal injection of aflibercept for DME in a patient with type 2 DM, which improved simply by discontinuing aflibercept, without the use of corticosteroids or other drugs.

Additionally, there have been several reports of the occurrence of clinical symptoms after the initiation of intravitreal injections of VEGFI, although histopathological examinations of renal biopsy specimens were not performed [1, 2]. The most common condition was worsening eGFR, others were proteinuria, hypertension, hypertensive cerebral hemorrhage, and relapsed minimal change disease [1, 2, 26, 30].

Kidney damage associated with DM is often irreversible [39]. However, proteinuria due to intravitreal injection of VEGFI may be reversible. In patients with a long history of DM, it would be difficult to determine whether the kidney damage is due to DM or intravitreal injection of VEGFI in the clinical course. If kidney damage develops after starting intravitreal injection of VEGFI, we recommend performing histopathological examination of renal biopsy and discontinuing VEGFI immediately.

This patient had no familial history of TMA and did not present clinical features or autoantibodies suggesting autoimmune disease. VEGFI-induced renal TMA rarely develops the classical hematologic abnormalities found in acute general TMA [40]. Our report is, however, limited by not confirming serum aflibercept level, serum VEGF level, haptoglobin level, and ADAMTS13 level. Nevertheless, we consider that it does not take away the merit of this case report, since it included a histopathological examination of renal biopsy specimen. In the future, repeat renal biopsy proving the disappearance of the TMA would further support our conclusion.

We reported a case of renal TMA that had probably been induced by intravitreal injection of aflibercept for DME. This is a precious report of pathologically investigated renal TMA due to intravitreal injection of aflibercept for DME in a patient with a history of type 2 DM, which improved simply by discontinuing intravitreal injections of aflibercept, without the use of corticosteroids or other drugs. It is therefore necessary to perform careful monitoring of the development of renal damage during intravitreal injection of aflibercept.

Availability of data and materials

Not applicable.

Change history

Abbreviations

ADPKD:

Autosomal dominant polycystic kidney disease

Aflib:

Aflibercept

AIN:

Acute interstitial nephritis

AMD:

Age-related macular degeneration

Bev:

Bevacizumab

BPH:

Benign prostatic hyperplasia

C1q:

Complement component 1q

C3:

Complement component 3

C4c:

Complement component 4

CAD:

Coronary artery disease

CC:

Corticosteroids

cFSGS:

Collapsing focal and segmental sclerosis

CKD:

Chronic Kidney Disease

CKD-EPI:

Chronic Kidney Diseases – Epidemiology Collaboration

COPD:

Chronic obstructive pulmonary disease

CyA:

Cyclophosphamide

DM:

Diabetic mellitus

DME:

Diabetic macular edema

DN:

Diabetic nephropathy

DR:

Diabetic retinopathy

ESRD:

End-stage renal disease

FPI:

Fresh plasma infusion

GBM:

Glomerular basement membrane

HD:

Hemodialysis

HNS:

Hypertensive nephrosclerosis

HT:

Hypertension

IgA:

Immunoglobulin A

IgG:

Immunoglobulin G

IgM:

Immunoglobulin M

IVIG:

Intravenous immunoglobulin

M:

Months

MD:

Macular degeneration

MGN:

Membranous glomerulonephritis

MMF:

Mycophenolate mofetil

NR:

Not recorded

Paf:

Paroxysmal atrial fibrillation

PE:

Plasma exchange

PSL:

Prednisone

Ran:

Ranibizumab

SSc:

Systemic sclerosis

T1DM:

Type 1 diabetic mellitus

T2DM:

Type 2 diabetic mellitus

TMA:

Thrombotic microangiopathy

VEGF:

Vascular endothelial growth factor

VEGFI:

Vascular endothelial growth factor inhibitor

VEGFIs:

Vascular endothelial growth factor inhibitors

Y:

Years

References

  1. Hanna RM, Barsoum M, Arman F. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96(3):572–80. https://doi.org/10.1016/j.kint.2019.02.042.

    Article  CAS  Google Scholar 

  2. Hanna RM, Ahdoot RS, Kim MS, Jhaveri KD, Kalantar-Zadeh K, Kurtz IB. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review. Curr Opin Nephrol Hypertens. 2022;31(1):47–56. https://doi.org/10.1097/MNH.0000000000000760.

    Article  CAS  Google Scholar 

  3. Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol. 2019;30(2):187–200. https://doi.org/10.1681/ASN.2018080853.

    Article  CAS  Google Scholar 

  4. Amoaku WM, Ghanchi F, Bailey C, Banerjee S, Banerjee S, Downey L, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye (Lond). 2020;34(Suppl 1):1–51. https://doi.org/10.1038/s41433-020-0961-6.

    Article  Google Scholar 

  5. Tschulakow A, Christner S, Julien S, Ludinsky M, Giet M, Schraermeyer U. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys. PLoS ONE. 2014;9(11): e113701. https://doi.org/10.1371/journal.pone.0113701.

    Article  CAS  Google Scholar 

  6. Glassman AR, Liu D, Jampol LM, Sun JK. Diabetic Retinopathy Clinical Research Network. Changes in blood pressure and urine albumin-creatinine ratio in a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. Invest Ophthalmol Vis Sci. 2018;59(3):1199–205. https://doi.org/10.1167/iovs.17-22853.

    Article  CAS  Google Scholar 

  7. Bagheri SD, Afarid M, Sagheb MM. Proteinuria and renal dysfunction after intravitreal injection of bevacizumab in patients with diabetic nephropathy: a prospective observational study. Galen Med J. 2018;7:e1299. https://doi.org/10.22086/gmj.v0i0.1299.

    Article  Google Scholar 

  8. Kameda Y, Babazono T, Uchigata Y, Kitano S. Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease. J Diabetes Investig. 2018;9(4):937–9. https://doi.org/10.1111/jdi.12771.

    Article  CAS  Google Scholar 

  9. O’Neill RA, Gallagher P, Douglas T, Little JA, Maxwell AP, Silvestri G, et al. Evaluation of longterm intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease. BMC Nephrol. 2019;20(1):478. https://doi.org/10.1186/s12882-019-1650-1.

    Article  CAS  Google Scholar 

  10. Jalalonmuhali M, Kamalden TAFT, Ismail NS, Yong SY, Teo WT, Lim SK. Adverse renal outcome following administration of intravitreal anti-vascular endothelial growth factor inhibitors in a single tertiary centre in Malaysia. Nephrol Dial Transplant. 2020;142:590. https://doi.org/10.1093/ndt/gfaa142.P0590.

    Article  Google Scholar 

  11. Chung YR, Kim YH, Byeon HE, Jo DH, Kim JH, Lee K. Effect of a single intravitreal injection of bevacizumab on proteinuria in patients with diabetes. Transl Vis Sci Technol. 2020;9(4):4. https://doi.org/10.1167/tvst.9.4.4.

    Article  Google Scholar 

  12. Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond). 2009;23(8):1714–8. https://doi.org/10.1038/eye.2008.360.

    Article  CAS  Google Scholar 

  13. Lee K, Yang H, Lim H, Lew HM. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. Retina. 2009;29(10):1409–17. https://doi.org/10.1097/IAE.0b013e3181b21056.

    Article  Google Scholar 

  14. Risimic D, Milenkovic S, Nikolic D, Simeunovic D, Jaksic V, Stojkovic M, et al. Influence of intravitreal injection of bevacizumab on systemic blood pressure changes in patients with exudative form of age-related macular degeneration. Hellenic J Cardiol. 2013;54(6):435–40.

    Google Scholar 

  15. Shah AR, Van Horn AN, Verchinina L, Wichorek M, Su L, Markel D, et al. Blood pressure is associated with receiving intravitreal anti-vascular endothelial growth factor treatment in patients with diabetes. Opththalmol Retina. 2019;3(5):410–6. https://doi.org/10.1016/j.oret.2019.01.019.

    Article  Google Scholar 

  16. Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and metaanalysis. JAMA Ophthalmol. 2016;134(1):21–9. https://doi.org/10.1001/jamaophthalmol.2015.4070.

    Article  Google Scholar 

  17. Hanhart J, Comaneshter DS, Freier Dror Y, Vinker S. Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration. BMC Ophthalmol. 2017;17(1):189. https://doi.org/10.1186/s12886-017-0586-0.

    Article  CAS  Google Scholar 

  18. Hanhart J, Comaneshter DS, Freier-Dror Y, Vinker S. Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):651–63. https://doi.org/10.1007/s00417-018-3917-9.

    Article  CAS  Google Scholar 

  19. Hanhart J, Comaneshter DS, Vinker S. Mortality after a cerebrovascular event in age-related macular degeneration patients treated with bevacizumab ocular injections. Acta Ophthalmol. 2018;96(6):e732–9. https://doi.org/10.1111/aos.13731.

    Article  CAS  Google Scholar 

  20. Dalvin LA, Starr MR, AbouChehade JE, Damento GM, Garcia M, Shah SM, et al. Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration. JAMA Ophthalmol. 2019;137(5):483–90. https://doi.org/10.1001/jamaophthalmol.2018.6891.

    Article  Google Scholar 

  21. Pellé G, Shweke N, Van Huyen J-PD, Tricot L, Hessaïne S, Frémeaux-Bacchi V, et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis. 2011;57(5):756–9. https://doi.org/10.1053/j.ajkd.2010.11.030.

    Article  CAS  Google Scholar 

  22. Anto HR, Hyman GF, Li JP, Spitalewitz S, Thomas D. Membranous nephropathy following intravitreal injection of bevacizumab. Can J Ophthalmol. 2012;47(1):84–6. https://doi.org/10.1016/j.jcjo.2011.12.024.

    Article  Google Scholar 

  23. Cheungpasitporn W, Chebib FT, Cornell LD, Brodin ML, Nasr SH, Schinstock CA, et al. Intravitreal anti-vascular endothelial growth factor therapy may induce proteinuria and antibody mediated injury in renal allografts. Transplant. 2015;99(11):2382–6. https://doi.org/10.1097/TP.0000000000000750.

    Article  CAS  Google Scholar 

  24. Khneizer G, Al-Taee A, Bastani B. Self-limited membranous nephropathy after Intravitreal nephropathy after intravitreal bevacizumab therapy for age related macular degeneration. J Nephropathol. 2017;6(3):134–7. https://doi.org/10.15171/jnp.2017.23.

    Article  Google Scholar 

  25. Valsan D, Kazi S. Intravitreal VEGF inhibitor causing allergic interstitial nephritis. Am J Kidney Dis. 2017;69(4):A99. https://doi.org/10.1053/j.ajkd.2017.02.339.

    Article  Google Scholar 

  26. Hanna RM, Lopez E, Hasnain H, Selamet U, Wilson J, Youssef PN, et al. Three patients with injection of intravitreal vascular endothelial growth facto inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J. 2019;12(1):92–100. https://doi.org/10.1093/ckj/sfy060.

    Article  CAS  Google Scholar 

  27. Nobakht NN, Nguyen HA, Kamgar MK, Abdelnour L, Rastogi A, Hanna RM. Development of collapsing focal and segmental glomerulosclerosis in a patient receiving intravitreal vascular endothelial growth factor blockade. Kidney Int Rep. 2019;4(10):1508–12. https://doi.org/10.1016/j.ekir.2019.07.019.

    Article  Google Scholar 

  28. Touzani F, Geers C, Pozdzik A. Intravitreal injection of antiVEGF antibody induces glomerular endothelial cells injury. Case Rep Nephrol. 2019;2019:2919080. https://doi.org/10.1155/2019/2919080.

    Article  CAS  Google Scholar 

  29. Yin W, Zhang PL. Intravitreal injection of avastin (IIA) over time can be associated with thromobtic microangiopathy (TMA) in the native kidney. J Am Soc Nephrol. 2019;30:153-4.

  30. Shye M, Hanna RM, Patel SS, Tram-Tran N, Hou J, Mccannel C, et al. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. Clin Kidney J. 2020;13(6):969–80. https://doi.org/10.1093/ckj/sfaa049.

    Article  CAS  Google Scholar 

  31. Kakeshita K, Koike T, Imamura T, Murai S, Fujioka H, Yamazaki H, et al. Nephrotic syndrome with focal segmental glomerulosclerosis induced by intravitreal injections of vascular endothelial growth factor inhibitor. Intern Med. 2020;59(23):5410–20. https://doi.org/10.2169/internalmedicine.5410-20.

    Article  Google Scholar 

  32. Hanna RM, Tran NT, Patel SS, Hou J, Jhaveri KD, Parikh R, et al. Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF blockade-related TMA after intravitreal use. Front Med (Lausanne). 2020;7:579603. https://doi.org/10.3389/fmed.2020.579603.

    Article  Google Scholar 

  33. Hanna RM, Abdelnour L, Zuckerman JE, Ferrey AJ, Pai A, Vahabzadeh K, et al. Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab. SAGE Open Med Case Rep. 2020;8:2050313X20952650. https://doi.org/10.1177/2050313X20952650.

    Article  Google Scholar 

  34. Phadke G, Hanna RM, Ferrey AJ, Torres EA, Singla A, Kaushal A, et al. Review of intravitreal vascular endothelial growth factor inhibitor toxcitiy, and report of collpasing focal and segmental sclerosis with thrombotic microangiopathy in a patient with age-related macular degeneration. Clin Kidney J. 2021;14(10):2158–65. https://doi.org/10.1093/ckj/sfab066.

    Article  Google Scholar 

  35. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98(12):1636–41. https://doi.org/10.1136/bjophthalmol-2014-305252.

    Article  Google Scholar 

  36. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847–58. https://doi.org/10.1097/IAE.0000000000001493.

    Article  CAS  Google Scholar 

  37. Sadiq MA, Halim MS, Hassan M, Onghanseng N, Karaca I, Agarwal A, et al. Pharmacological agents in development for diabetic macular edema. Int J Retina Vitreous. 2020;6:29. https://doi.org/10.1186/s40942-020-00234-z.

    Article  Google Scholar 

  38. Laszik ZG, Kambham N, Silva FG. Thrombotic Microangiopathies. In: Jannette JC, Olson JL, Silva FG, D’Agati VD, editors. Heptinstall’s Pathology of the Kidney, vol. II. 7th ed. Philadelphia, PA, USA: Wolters Kluwer; 2015. p. 739–814.

    Google Scholar 

  39. Vincenzo AD, Battini S, Russo L, Mazzocut S, Mauer M, Fioretto P. Renal structure in type 2 diabetes: facts and misconceptions. J Nephrol. 2020;33(5):901–7. https://doi.org/10.1007/s40620-020-00797-y.

    Article  Google Scholar 

  40. Person F, Rinschen MM, Brix SR, Wulf S, Noriega MM, Fehrle W, et al. Bevacizumab-associated glomerular microangiopathy. Mod Pathol. 2019;32(5):684–700. https://doi.org/10.1038/s41379-018-0186-4.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Not applicable.

Author information

Author notes

  1. Yawara Kikuchi and Yoshimi Odashima contributed equally to this work.

Authors and Affiliations

  1. Division of Nephrology and Hypertension, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan

    Yawara Kikuchi, Kazuhiro Yoshikawa, Fumitaka Tanaka & Koichi Asahi

  2. Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan

    Yoshimi Odashima, Tomoyasu Oda & Yasushi Ishigaki

  3. Department of Internal Medicine, Morioka Tsunagi Onsen Hospital, Morioka, Japan

    Hiroki Oikawa

Authors
  1. Yawara Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshimi Odashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuhiro Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomoyasu Oda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fumitaka Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroki Oikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasushi Ishigaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Koichi Asahi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YK, YO, and KY wrote the manuscript and were physicians for the patient, and KY carried out final preparation of the manuscript. TO, MH, and MS were also physicians for the patient. HO performed and evaluated renal biopsy specimens. FT, YI, and KA participated in discussion of the patient’s treatment. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Kazuhiro Yoshikawa.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for the publication of this case report. A copy of the written consent is available for review by the Editor of this journal.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised: the authors replaced the Supplementary information.

Supplementary Information

Additional file 1: Table 1.

Summary of literature on renal biopsy after intravitreal injection of vascular endothelial growth factor inhibitors.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kikuchi, Y., Odashima, Y., Yoshikawa, K. et al. Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema. BMC Nephrol 23, 348 (2022). https://doi.org/10.1186/s12882-022-02986-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12882-022-02986-2

Keywords

BMC Nephrology

ISSN: 1471-2369

Contact us